In this episode, Anousha is joined by Dr. Su Wang, Medical Director of the Chinese Medical Program at Cooperman Barnabas Medical Center and Medical Advisor to the Hepatitis B Foundation, along with Dr. Thomas Tu, Molecular Biologist at the Westmead Institute for Medical Research in Australia. Together, they discuss expanding hepatitis B treatment guidelines by broadening eligibility criteria, improving access, reducing loss to follow-up, and the importance of including public health and patie...
All content for B Heppy is the property of Hepatitis B Foundation and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
In this episode, Anousha is joined by Dr. Su Wang, Medical Director of the Chinese Medical Program at Cooperman Barnabas Medical Center and Medical Advisor to the Hepatitis B Foundation, along with Dr. Thomas Tu, Molecular Biologist at the Westmead Institute for Medical Research in Australia. Together, they discuss expanding hepatitis B treatment guidelines by broadening eligibility criteria, improving access, reducing loss to follow-up, and the importance of including public health and patie...
In this episode, Anousha and Bright invited Dr. Robert Gish to speak about hepatitis B Reactivation, a serious health issue often overlooked in the discourse surrounding hepatitis B and liver cancer.Learn more about Dr. Gish at his website www.robertgish.com as well as through his podcast linked below. Everything Liver Podcast: https://www.robertgish.com/podcastSupport the showOur website: www.hepb.orgSupport B Heppy!Social Media: Instagram - Twitter - Facebook
B Heppy
In this episode, Anousha is joined by Dr. Su Wang, Medical Director of the Chinese Medical Program at Cooperman Barnabas Medical Center and Medical Advisor to the Hepatitis B Foundation, along with Dr. Thomas Tu, Molecular Biologist at the Westmead Institute for Medical Research in Australia. Together, they discuss expanding hepatitis B treatment guidelines by broadening eligibility criteria, improving access, reducing loss to follow-up, and the importance of including public health and patie...
